Biogerontology

, Volume 5, Issue 1, pp 55–61 | Cite as

Proteasome inhibition induces a senescence-like phenotype in primary human fibroblasts cultures

Article

Abstract

Senescent human fibroblasts exhibit several genetic and biochemical differences as compared to their young counterparts including abnormalities of the main proteolytic mechanism, namely the proteasome. Specifically,we and others have shown that there is an impaired function of the proteasome, as senescent cells have reduced proteolytic activities and less proteasome content. In a complementary work we have recently shown that inhibition of the proteasome by a specific inhibitor induces a senescence-like phenotype in young WI38 fibroblasts [Chondrogianni et al. (2003)J Biol Chem 278: 28026–28037]. In this study we tested whether the induction of a senescence-like phenotype following treatment with proteasome inhibitors is a common feature of primary human fibroblasts. A comparative biochemical analysis, after employing three different human fibroblasts cell lines (IMR90, MRC5 and WI38 cells), as well as two proteasome inhibitors(epoxomicin and MG132), has shown that proteasome inhibition results in the appearance of a senescence-like phenotype in all cell lines used. Proteasome inhibitors treated cells were irreversibly stopped dividing, exhibited positive staining to β-galactosidase as well as reduced CT-L and PGPH activities. In summary, these data reveal the fundamental role of the proteasome in the progression of replicative senescence and open new dimensions towards a better understanding of protein degradation.

ageing epoxomicin human fibroblasts MG132 proteasome inhibition senescence 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Brooks P, Murray RZ, Mason GG, Hendil KB and Rivett AJ (2000) Association of immunoproteasomes with the endoplasmic reticulum. Biochem J 352: 611-615PubMedGoogle Scholar
  2. Bulteau AL, Petropoulos I and Friguet B (2000) Age-related alterations of proteasome structure and function in aging epidermis. Exp Gerontol 35: 767-777PubMedGoogle Scholar
  3. Bulteau AL, Szweda LI and Friguet B (2002) Age-dependent declines in proteasome activity in the heart. Arch Biochem Biophys 397: 298-304PubMedGoogle Scholar
  4. Campisi J (2001) From cells to organisms: can we learn about aging from cells in culture? Exp Gerontol 36: 607-618PubMedGoogle Scholar
  5. Chondrogianni N, Petropoulos I, Franceschi C, Friguet B and Gonos ES (2000) Fibroblasts cutures from healthy centenarians have an active proteasome. Exp Gerontol 35: 721-728PubMedGoogle Scholar
  6. Chondrogianni N, Fragoulis EG and Gonos ES (2002) Protein degaradation during aging: the lysosome-, the calpain-and the proteasome-dependent cellular proteolytic systems. Biogerontology 3: 121-123PubMedGoogle Scholar
  7. Chondrogianni N, Stratford FLL, Trougakos IP, Friguet B, Rivett AJ and Gonos ES (2003) Central role of the proteasome in senescence and survival of human fibroblasts: induction of a senescence-like phenotype upon its inhibition and resistance to stress upon its activation. J Biol Chem 278: 28026-28037PubMedGoogle Scholar
  8. Davies KJ (1999) The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. IUBMB Life 48: 41-47PubMedGoogle Scholar
  9. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubel I, Pereira-Smith O, Peacocke M and Campisi J (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 9363-9367PubMedGoogle Scholar
  10. Franco S, MacKenzie KL, Dias S, Alvarez S, Rafii S and Moore MAS (2001) Clonal variation in phenotype and lifespan of human embryonic fibroblasts (MRC-5) transduced with the catalytic component of telomerase (hTERT). Exp Cell Res 268: 14-25PubMedGoogle Scholar
  11. Fonager J, Beedholm R, Clark BF and Rattan SIS (2002) Mild stress-induced stimulation of heat-shock protein synthesis and improved functional ability of human fibroblasts undergoing aging in vitro. Exp Gerontol 37: 1223-1228PubMedGoogle Scholar
  12. Gaczynska M, Osmulski PA and Ward WF (2001) Caretaker or undertaker? The role of the proteasome in aging. Mech Ageing Dev 122: 235-254PubMedGoogle Scholar
  13. Harlow E and Lane D (1999) Using Antibodies: a Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New YorkGoogle Scholar
  14. Hendil KB, Kristensen P and Uerkvitz W (1995) Human proteasomes analysed with monoclonal antibodies. Biochem J 305: 245-252PubMedGoogle Scholar
  15. Kikuchi S, Shinpo K, Takeuchi M, Yamagishi S, Makita Z, Sasaki N and Tashiro K (2003) Glycation: a sweet tempter for neuronal death. Brain Res Brain Res Rev 41: 306-323PubMedGoogle Scholar
  16. Lee DH and Goldberg AL (1998) Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 8: 397-403PubMedGoogle Scholar
  17. Merker K and Grune T (2000) Proteolysis of oxidised proteins and cellular senescence. Exp Gerontol 35: 779-786PubMedGoogle Scholar
  18. Merker K, Sitte N and Grune T (2000) Hydrogen peroxide-mediated protein oxidation in young and old human MRC-5 fibroblasts. Arch Biochem Biophys 375: 50-54PubMedGoogle Scholar
  19. Petropoulos I, Conconi M, Wang X, Hoenel B, Brégègére F and Friguet B (2000) Increase of oxidatively modified protein is associated with decrease of proteasome activity and content in aging epidermal cells. J Gerontol Biol Sci Med Sci 55: B220-B227Google Scholar
  20. Rattan SIS (2001) Applying hormesis in aging research and therapy. Hum Exp Toxicol 20: 281-285PubMedGoogle Scholar
  21. Serra V, von Zglinicki T, Lorenz M and Saretzki G (2003) Extracellular superoxide dismutase is a major antioxidant in human fibroblasts and slows telomere shortening. J Biol Chem 278: 6824-6830PubMedGoogle Scholar
  22. Sin N, Kim KB, Elofsson M, Meng L, Auth H, Kwok BH and Crews CM (1999) Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett 9: 2283-2288PubMedGoogle Scholar
  23. Sitte N, Merker K, von Zglinicki T, Grune T and Davies KJA (2000a) Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part I - effects of proliferative senescence. FASEB J 14: 2495-2502PubMedGoogle Scholar
  24. Sitte N, Merker K, von Zglinicki T, Grune T and Davies KJA (2000b) Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part II - aging of nondividing cells. FASEB J 14: 2503-2510PubMedGoogle Scholar
  25. Sitte N, Merker K, von Zglinicki T and Grune T (2000c) Protein oxidation and degradation during proliferative senescence of human MRC-5 fibroblasts. Free Radic Biol Med 28: 701-708PubMedGoogle Scholar
  26. Tsubuki S, Saito Y, Tomioka M, Ito H and Kawashima S (1996) Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem 119: 572-576PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  1. 1.National Hellenic Research Foundation, Institute of Biological Research and BiotechnologyAthensGreece

Personalised recommendations